Ohio State University College of Medicine

CalciMedica Announces Upcoming Presentations and Events in September

Retrieved on: 
Wednesday, September 6, 2023
IR, Nutrition, Emergency medicine, Ohio State University College of Dentistry, CRAC, Henry Ford Health, Associate, Emergency, Ohio State University College of Medicine, Michigan State University, Conference, Pharmaceutical industry, Gastroenterology

LA JOLLA, Calif., Sept. 6, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023, at 1:30 p.m. – 2:00 p.m. ET/ 10:30 a.m. – 11 a.m. PT.

Key Points: 
  • LA JOLLA, Calif., Sept. 6, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023, at 1:30 p.m. – 2:00 p.m. ET/ 10:30 a.m. – 11 a.m. PT.
  • The Company will also be hosting a virtual Acute Pancreatitis Clinical Experts Event on Thursday, September 21, 2023, from 10:30 a.m. – 12 p.m. ET/ 7:30 a.m. – 9 a.m. PT featuring Joseph Miller, M.D., Clinical Associate Professor of Emergency Medicine at Henry Ford Health and Michigan State University and Associate Director of Emergency Care Research at Henry Ford Health, and Georgios Papachristou, M.D., Ph.D., Professor of Medicine, Floyd Beman Endowed Chair in Gastroenterology and division director for Gastroenterology, Hepatology and Nutrition at The Ohio State University College of Medicine.
  • Live webcasts of both events, as well as registration for the clinical experts event, can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/ .
  • A replay of the Acute Pancreatitis Clinical Experts Event will be available for one year following the completion of the event, and a replay of the conference presentation will be available for 90 days.

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

Retrieved on: 
Thursday, August 31, 2023
Ohio State University College of Dentistry, Michigan State University, CRAC, Ohio State University College of Medicine, IR, Emergency medicine, Henry Ford Health, Nutrition, Emergency, Pharmaceutical industry, Gastroenterology, Medicine

LA JOLLA, Calif., Aug. 31, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a virtual clinical experts event on Thursday, September 21, 2023, from 10:30 a.m. – 12 p.m. ET/ 7:30 a.m. – 9 a.m. PT.

Key Points: 
  • LA JOLLA, Calif., Aug. 31, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a virtual clinical experts event on Thursday, September 21, 2023, from 10:30 a.m. – 12 p.m. ET/ 7:30 a.m. – 9 a.m. PT.
  • CalciMedica management will be joined by clinical experts Joseph Miller, M.D., clinical associate professor of Emergency Medicine at Henry Ford Health and Michigan State University and associate director of Emergency Care Research at Henry Ford Health, and Georgios Papachristou, M.D., Ph.D., professor of Medicine, Floyd Beman Endowed Chair in Gastroenterology and division director for Gastroenterology, Hepatology and Nutrition at The Ohio State University College of Medicine in discussing the Company's lead clinical compound, Auxora™, and its potential implications in acute pancreatitis.
  • Registration for the event will be available in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/ beginning at 7:30 a.m.
  • ET on Wednesday, September 6.

BioVaxys and The Ohio State University Extend Research Collaboration

Retrieved on: 
Wednesday, August 30, 2023
Vaccine, Infection, Ohio State University, Molecular epidemiology, Bachelor, Nextgen, CSE, University, Prevalence, Vaccination, Environmental science, SARS-CoV-2, Public, United States Department of Defense, COVID-19, Immunity, Mutation, Research, FRA, Doctor of Philosophy, Government, Animal science, COVID-19 vaccine, Animal, Risk, OTC, Viral, Privacy and the US government, Diagnosis, SAM, Ohio State University College of Medicine, Virus, NIH, World Health Organization, Pharmaceutical industry

VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.

Key Points: 
  • VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.
  • This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.
  • There are growing concerns about the recently emerging Covid-19 variant EG.5 ("EG.5").
  • The collaborating laboratory at The Ohio State University is led by virologist Professor Qiuhong Wang, Bachelor of Medicine (China) and PhD (USA), from the University's Center for Food Animal Health , Department of Animal Sciences, College of Food, Agricultural, & Environmental Sciences.

BioVaxys and The Ohio State University Extend Research Collaboration

Retrieved on: 
Wednesday, August 30, 2023
Vaccine, Infection, Ohio State University, Molecular epidemiology, Bachelor, Nextgen, CSE, University, Prevalence, Vaccination, Environmental science, SARS-CoV-2, Public, United States Department of Defense, COVID-19, Immunity, Mutation, Research, FRA, Doctor of Philosophy, Government, Animal science, COVID-19 vaccine, Animal, Risk, OTC, Viral, Privacy and the US government, Diagnosis, SAM, Ohio State University College of Medicine, Virus, NIH, World Health Organization, Pharmaceutical industry

VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.

Key Points: 
  • VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.
  • This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.
  • There are growing concerns about the recently emerging Covid-19 variant EG.5 ("EG.5").
  • The collaborating laboratory at The Ohio State University is led by virologist Professor Qiuhong Wang, Bachelor of Medicine (China) and PhD (USA), from the University's Center for Food Animal Health , Department of Animal Sciences, College of Food, Agricultural, & Environmental Sciences.

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023
University college, Clinical trial, Patient, Ohio State University College of Medicine, AACR, Poster, ALK, Cancer, American Association for Cancer Research, NSCLC, South Korea, Lung cancer, Pharmaceutical industry

The data, resulting from a collaboration with the Yonsei University College of Medicine, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

Key Points: 
  • The data, resulting from a collaboration with the Yonsei University College of Medicine, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.
  • The poster describes the preclinical intracranial antitumor activity of NVL-655 in a brain-implanted xenograft model derived from a patient with lung cancer harboring the alectinib-resistant EML4-ALK v3 G1202R mutation.
  • The poster will be archived on the Nuvalent website at www.nuvalent.com following the presentation.
  • Details for the poster presentation are as follows:
    1Yonsei University College of Medicine, Seoul, Republic of Korea 2Nuvalent Inc., Cambridge, MA, USA

Childhood Brain Tumor Expert Joins Hassenfeld Children's Hospital at NYU Langone as Director of Pediatric Neuro-Oncology

Retrieved on: 
Tuesday, December 20, 2022
Hospital, Neurosurgery, Patient, Nationwide Children's Hospital, Harvard Medical School, Boston Children's Hospital, Brain, Ann, New York University Grossman School of Medicine, Diagnosis, NYU Langone Health, University college, MD, Degenerative disease, Pediatrics, Marie Cassidy, Ohio State University College of Medicine, Hassenfeld Children's Hospital, Dana–Farber Cancer Institute, PAT, Research, NYU, Medicine, Dentistry, Cancer

Prior to Hassenfeld Children's Hospital, Dr. Clymer was a clinician at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

Key Points: 
  • Prior to Hassenfeld Children's Hospital, Dr. Clymer was a clinician at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
  • She was also an instructor in the Department of Pediatrics and director of the Neuro-Oncology Fellowship at Harvard Medical School.
  • Hassenfeld Children's Hospital offers the latest technologies and early clinical trials, expanding overall treatment options and patient success rates.
  • She went on to complete a fellowship in pediatric hematology/oncology at Ann and Robert M. Lurie Children's Hospital of Chicago and a pediatric neuro-oncology fellowship within Dana-Farber Cancer Institute and Boston Children's Hospital.

Baszucki Group hires former executives of CURE Epilepsy and DietDoctor to advance initiatives at the intersection of metabolism and mental health

Retrieved on: 
Monday, November 14, 2022
Epilepsy, SAN, Doctor of Philosophy, Washington University in St. Louis, Metabolism, Ohio State University College of Medicine, Health, Roblox, Democracy, MD, Therapy, Awareness, CURE, University, Industry, Mental health, Research, BS, Investment, Patient, Stanford University, University college, CEO, Jazz Pharmaceuticals, Bipolar disorder, University of Colorado Denver, Associate, Longevity, Psychiatry, Medical device, Pharmaceutical industry, Neuroscience, Biology

SAN MATEO, Calif., Nov. 14, 2022 /PRNewswire/ -- Baszucki Group today announced it has added two key executives from the medical and scientific fields to advance its philanthropic mission. Julie Milder, PhD, formerly of CURE Epilepsy, and Bret Scher, MD, formerly of DietDoctor.com, bring considerable expertise in neuroscience and metabolic health to the Baszucki Group's leadership team.

Key Points: 
  • Julie Milder, PhD, formerly of CURE Epilepsy, and Bret Scher, MD, formerly of DietDoctor.com, bring considerable expertise in neuroscience and metabolic health to the Baszucki Group's leadership team.
  • "Dr. Milder will leverage her experience in neuroscience, nonprofit grantmaking and industry to optimize Baszucki Group's research portfolios.
  • Dr. Milder directed grantmaking and collaborative team science initiatives for CURE Epilepsy, the largest non-governmental funder of epilepsy research.
  • A primary objective of Baszucki Group is to transform mental health outcomes, beginning with bipolar disorder, by supporting initiatives at the intersection of metabolism, psychiatry and neuroscience.

Kroger Health/Ralphs Pharmacy and Cardinal Health to Host Drug Take Back Events on Saturday, October 29, 2022

Retrieved on: 
Friday, October 21, 2022
Zero, Human spirit, KR, Medicine, Ohio State University College of Medicine, Drug, NYSE, Ralphs, National, Gel, Jefferson Boulevard, Multimedia, Garfield, Partnership, Spirit, Kroger, Plasma protein binding, Naloxone, Drug Enforcement Administration, Practitioner, Health, Pharming, Health policy, OTC, Hunger, Food, Pharmacist, Prescription drug, Generation Rx, Cannon, Supermarket, Prescription, Cardinal Health, Health insurance, Grocery store, Pharmaceutical industry, Pharmacy

LOS ANGELES, Oct. 21, 2022 /PRNewswire/ -- Kroger/Ralphs, as part of Kroger Health, and Cardinal Health will be working together again to host their annual drug take back events at more than 150 local pharmacy locations across the country.

Key Points: 
  • LOS ANGELES, Oct. 21, 2022 /PRNewswire/ -- Kroger/Ralphs, as part of Kroger Health, and Cardinal Health will be working together again to host their annual drug take back events at more than 150 local pharmacy locations across the country.
  • These events will take place on Saturday, October 29, the Drug Enforcement Administration's National Prescription Drug Take Back Day.
  • "At Cardinal Health, it's always a priority for us to help lead the fight against prescription medication misuse," saidJessie Cannon, vice president of community relations at Cardinal Health.
  • Cardinal Health has joined Kroger Health in hosting drug take back events across the U.S. for several years.

Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic

Retrieved on: 
Wednesday, October 19, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Wharton School of the University of Pennsylvania, Doctor of Philosophy, Molecular biology, Therapy, Indiana State University, University college, Growth, Bristol Myers Squibb, Drug development, Weill Cornell Graduate School of Medical Sciences, Genetic engineering, MBA, List of life sciences, Ohio State University College of Medicine, FU Orionis, Medicine, Investment, Cancer, Precision medicine, University, Graduate school, Drug discovery, Industry, Novartis, Board, CEO, Immunotherapy, Weill Cornell Medicine, Financial toxicity, Genetics, Fudan University, FDA, Management, Pharmaceutical industry

Founded in 2015, Orionis has since developed its proprietary technology platforms, grown a deep pipeline and cemented a drug discovery deal with Novartis.

Key Points: 
  • Founded in 2015, Orionis has since developed its proprietary technology platforms, grown a deep pipeline and cemented a drug discovery deal with Novartis.
  • This latest financing round provides the company with additional capital for R&D expansion, pipeline growth and advancement of its lead cancer immunotherapy programs into clinical trials.
  • Existing and new investors participated in the round, including Cormorant Asset Management, Novartis and a series of high-caliber investment funds.
  • In addition, we are pleased to welcome industry veteran Bihua Chen to our Board as we enter this next stage of growth.

Secant Group, Nationwide Children’s Hospital Collaborate to Advance Breakthrough Cardiovascular Technology

Retrieved on: 
Wednesday, September 14, 2022
Research, Pharmaceutical, Consumer, Medical Devices, Other Manufacturing, Textiles, Surgery, Science, Children, Cardiology, Biotechnology, Health, Manufacturing, Regenerative medicine, Health, Nationwide Children's Hospital, U.S. News & World Report, Pediatrics, Center, OH, Department, Hospital, National, MD, Research, News, Population, Compliance, Tissue engineering, Industry, Nationwide, Regeneration, Health equity, PGS, Technology, Ohio State University College of Medicine, Solution, Ventricular septal defect, Doctor of Philosophy, Genomics, AWRI, University college, Secant, Medical device

The Secant Group and Nationwide Childrens collaboration advances the development of implantable tissue-engineered vascular grafts (TEVGs) to treat conditions such as coronary artery defects in children.

Key Points: 
  • The Secant Group and Nationwide Childrens collaboration advances the development of implantable tissue-engineered vascular grafts (TEVGs) to treat conditions such as coronary artery defects in children.
  • The technology supporting the Secant Group-Nationwide Childrens collaboration is Secants novel biopolymer poly(glycerol sebacate) (PGS), a stealth material that does not overstimulate the bodys immune system.
  • As the contract developer and manufacturer of the TEVG implant, Secant Group is supporting the advancement of Nationwide Childrens research to develop a potential solution for repairing heart defects.
  • Integrated clinical and research programs are part of what allows Nationwide Childrens to advance its unique model of care.